{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T21:38:37Z","timestamp":1773265117201,"version":"3.50.1"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T00:00:00Z","timestamp":1618185600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.diabres.2021.108759","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T03:41:55Z","timestamp":1616038915000},"page":"108759","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["The long-term cost-effectiveness of oral semaglutide in the Netherlands based on the PIONEER 2, 3 and 4 randomized controlled trials"],"prefix":"10.1016","volume":"175","author":[{"given":"Samuel J.P.","family":"Malkin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barnaby","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eline L.","family":"Huisman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias S.","family":"Grand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barrie","family":"Chubb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2021.108759_b0005","first-page":"281","article-title":"The current total economic burden of diabetes mellitus in the Netherlands","volume":"75","author":"Peters","year":"2017","journal-title":"Neth J Med"},{"key":"10.1016\/j.diabres.2021.108759_b0010","unstructured":"Rijksinstituut voor volksgezondheid en milieu. Diabetes Mellitus 2018. Available at: https:\/\/www.volksgezondheidenzorg.info\/onderwerp\/diabetes-mellitus\/ [accessed July 17, 2020]."},{"key":"10.1016\/j.diabres.2021.108759_b0015","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0140-6736(10)60576-4","article-title":"Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial","volume":"376","author":"Ismail-Beigi","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2021.108759_b0020","doi-asserted-by":"crossref","unstructured":"ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560\u201372.","DOI":"10.1056\/NEJMoa0802987"},{"key":"10.1016\/j.diabres.2021.108759_b0025","doi-asserted-by":"crossref","unstructured":"UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837\u201353.","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"10.1016\/j.diabres.2021.108759_b0030","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2021.108759_b0035","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ahj.2005.09.015","article-title":"Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials","volume":"152","author":"Stettler","year":"2006","journal-title":"Am Heart J"},{"issue":"41","key":"10.1016\/j.diabres.2021.108759_b0040","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"2018","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2021.108759_b0045","unstructured":"Nederlands Huisartsen Genootschap [Dutch Society of General Practitioners]. Diabetes mellitus type 2. 2018. Available at: https:\/\/richtlijnen.nhg.org\/standaarden\/diabetes-mellitus-type-2 [accessed July 31, 2020]."},{"key":"10.1016\/j.diabres.2021.108759_b0050","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0706245","article-title":"Effect of a multifactorial intervention on mortality in type 2 diabetes","volume":"358","author":"Gaede","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2021.108759_b0055","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(11)60698-3","article-title":"Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial","volume":"378","author":"Griffin","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2021.108759_b0060","doi-asserted-by":"crossref","unstructured":"Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney PM, Blackwell L, Collins R, Keech A, Simes J, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371:117\u201325.","DOI":"10.1016\/S0140-6736(08)60104-X"},{"key":"10.1016\/j.diabres.2021.108759_b0065","doi-asserted-by":"crossref","unstructured":"UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703\u201313.","DOI":"10.1136\/bmj.317.7160.703"},{"key":"10.1016\/j.diabres.2021.108759_b0070","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/dom.13564","article-title":"Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for the treatment of type 2 diabetes mellitus in the UK","volume":"21","author":"Viljoen","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2021.108759_b0075","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s13300-018-0542-x","article-title":"Once-weekly semaglutide versus once-daily liraglutide for the treatment of type 2 diabetes: A long-term cost-effectiveness analysis in Estonia","volume":"10","author":"Malkin","year":"2019","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.diabres.2021.108759_b0080","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s13300-019-0630-6","article-title":"Management of patients with type 2 diabetes with once-weekly semaglutide versus dulaglutide, exenatide ER, liraglutide and lixisenatide: A cost-effectiveness analysis in the Danish setting","volume":"10","author":"G\u00e6de","year":"2019","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.diabres.2021.108759_b0085","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1007\/s12325-019-00965-y","article-title":"The management of type 2 diabetes with once-weekly semaglutide versus dulaglutide: A long-term cost-effectiveness analysis in Slovakia","volume":"36","author":"Malkin","year":"2019","journal-title":"Adv Ther"},{"key":"10.1016\/j.diabres.2021.108759_b0090","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.2337\/dc19-0883","article-title":"Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: The PIONEER 2 trial","volume":"42","author":"Rodbard","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2021.108759_b0095","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1001\/jama.2019.2942","article-title":"Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: The PIONEER 3 randomized clinical trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.diabres.2021.108759_b0100","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(19)31271-1","article-title":"Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial","volume":"394","author":"Pratley","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2021.108759_b0105","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.2337\/diacare.27.9.2262","article-title":"Guidelines for computer modeling of diabetes and its complications","volume":"27","author":"American Diabetes Association Consensus Panel","year":"2004","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1016\/j.diabres.2021.108759_b0110","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1185\/030079904X1980","article-title":"The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making","volume":"20","author":"Palmer","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.diabres.2021.108759_b0115","doi-asserted-by":"crossref","unstructured":"Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, Let al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin 2004;20(Suppl 1):S27\u201340.","DOI":"10.1185\/030079904X1980"},{"key":"10.1016\/j.diabres.2021.108759_b0120","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jval.2014.07.007","article-title":"Validation of the IMS CORE Diabetes Model","volume":"17","author":"McEwan","year":"2014","journal-title":"Value Health"},{"key":"10.1016\/j.diabres.2021.108759_b0125","unstructured":"Zorginstituut Nederland. Guideline for economic evaluations in healthcare. 2016. Available at: [accessed January 19, 2019]. https:\/\/english.zorginstituutnederland.nl\/publications\/reports\/2016\/06\/16\/guideline-for-economic-evaluations-in-healthcare."},{"key":"10.1016\/j.diabres.2021.108759_b0130","unstructured":"World Health Organisation. Global Health Observatory data repository: Life tables by country (Netherlands). 2018. Available at: [Last accessed July 16, 2020]. https:\/\/apps.who.int\/gho\/data\/view.main.61160?lang=en."},{"key":"10.1016\/j.diabres.2021.108759_b0135","doi-asserted-by":"crossref","unstructured":"Briggs AH, Weinstein MC, Fenwick EA Karnon J, Sculpher MJ, Paltiel AD, et al. Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--6. Value Health 2012;15:835\u201342.","DOI":"10.1016\/j.jval.2012.04.014"},{"key":"10.1016\/j.diabres.2021.108759_b0140","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1111\/dom.13804","article-title":"Incorporating and interpreting regulatory guidance on estimands in diabetes clinical trials: The PIONEER 1 randomized clinical trial as an example","volume":"21","author":"Aroda","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2021.108759_b0145","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline. Statistical principles for clinical trials E9. Feb 5, 1998. Available at: [accessed June 12, 2019]. https:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E9\/Step4\/E9_Guideline.pdf."},{"key":"10.1016\/j.diabres.2021.108759_b0150","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jval.2016.10.004","article-title":"Multivariate prediction equations for HbA1c lowering, weight change, and hypoglycemic events associated with insulin rescue medication in type 2 diabetes mellitus: Informing economic modeling","volume":"20","author":"Willis","year":"2017","journal-title":"Value Health"},{"key":"10.1016\/j.diabres.2021.108759_b0155","doi-asserted-by":"crossref","unstructured":"UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007;50:1140\u20137.","DOI":"10.1007\/s00125-007-0599-y"},{"key":"10.1016\/j.diabres.2021.108759_b0160","first-page":"618039","article-title":"The cost of diabetes-related complications: registry-based analysis of days absent from work","volume":"2013","author":"S\u00f8rensen","year":"2013","journal-title":"Econ Re Int"},{"key":"10.1016\/j.diabres.2021.108759_b0165","doi-asserted-by":"crossref","first-page":"e019864","DOI":"10.1136\/bmjopen-2017-019864","article-title":"A cost of illness study of hypoglycaemic events in insulin-treated diabetes in the Netherlands","volume":"8","author":"de Groot","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.diabres.2021.108759_b0170","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jval.2014.03.003","article-title":"Review of utility values for economic modeling in type 2 diabetes","volume":"17","author":"Beaudet","year":"2014","journal-title":"Value Health"},{"key":"10.1016\/j.diabres.2021.108759_b0175","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1477-7525-11-90","article-title":"Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries","volume":"11","author":"Evans","year":"2013","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.diabres.2021.108759_b0180","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1111\/j.1464-5491.2005.01657.x","article-title":"Evaluation of the association between the EQ-5D (health-related utility) and body mass index (obesity) in hospital-treated people with Type 1 diabetes, Type 2 diabetes and with no diagnosed diabetes","volume":"22","author":"Lee","year":"2005","journal-title":"Diabet Med"},{"key":"10.1016\/j.diabres.2021.108759_b0185","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s13300-019-00736-6","article-title":"Oral semaglutide versus empagliflozin, sitagliptin and liraglutide in the UK: Long-term ost-effectiveness analyses based on the PIONEER clinical Ttial programme","volume":"11","author":"Bain","year":"2020","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.diabres.2021.108759_b0190","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.2337\/dc13-0331","article-title":"Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people","volume":"36","author":"Khunti","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2021.108759_b0195","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.pcd.2016.09.003","article-title":"Clinical inertia to insulin initiation and intensification in the UK: A focused literature review","volume":"11","author":"Khunti","year":"2017","journal-title":"Prim Care Diabetes"},{"key":"10.1016\/j.diabres.2021.108759_b0200","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/dom.13088","article-title":"Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review","volume":"20","author":"Khunti","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2021.108759_b0205","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/dom.12626","article-title":"Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin","volume":"18","author":"Khunti","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2021.108759_b0210","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/dom.13955","article-title":"Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk","volume":"22","author":"Husain","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2021.108759_b0215","doi-asserted-by":"crossref","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA et al. (LEADER Trial Investigators). Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311\u201322.","DOI":"10.1056\/NEJMoa1603827"},{"key":"10.1016\/j.diabres.2021.108759_b0220","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"(EMPA-REG OUTCOME Investigators). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2021.108759_b0225","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1161\/CIRCULATIONAHA.118.039177","article-title":"Empagliflozin and the risk of heart failure hospitalization in routine clinical care","volume":"139","author":"Patorno","year":"2019","journal-title":"Circulation"},{"issue":"43","key":"10.1016\/j.diabres.2021.108759_b0230","first-page":"487","article-title":"A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"2020","author":"Buse","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2021.108759_b0235","first-page":"1","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"00","author":"Cosentino","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.diabres.2021.108759_b0240","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1056\/NEJMoa021778","article-title":"Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes","volume":"348","author":"G\u00e6de","year":"2003","journal-title":"N Engl J Med"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822721001121?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822721001121?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:15:18Z","timestamp":1759173318000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822721001121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":48,"alternative-id":["S0168822721001121"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2021.108759","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The long-term cost-effectiveness of oral semaglutide in the Netherlands based on the PIONEER 2, 3 and 4 randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2021.108759","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"108759"}}